» Articles » PMID: 36732332

Immunological Correlates of Protection Following Vaccination with Glucan Particles Containing Cryptococcus Neoformans Chitin Deacetylases

Overview
Journal NPJ Vaccines
Date 2023 Feb 2
PMID 36732332
Authors
Affiliations
Soon will be listed here.
Abstract

Vaccination with glucan particles (GP) containing the Cryptococcus neoformans chitin deacetylases Cda1 and Cda2 protect mice against experimental cryptococcosis. Here, immunological correlates of vaccine-mediated protection were explored. Studies comparing knockout and wild-type mice demonstrated CD4 T cells are crucial, while B cells and CD8 T cells are dispensable. Protection was abolished following CD4 T cell depletion during either vaccination or infection but was retained if CD4 T cells were only partially depleted. Vaccination elicited systemic and durable antigen-specific immune responses in peripheral blood mononuclear cells (PBMCs), spleens, and lungs. Following vaccination and fungal challenge, robust T-helper (Th) 1 and Th17 responses were observed in the lungs. Protection was abrogated in mice congenitally deficient in interferon (IFN) γ, IFNγ receptor, interleukin (IL)-1β, IL-6, or IL-23. Thus, CD4 T cells and specific proinflammatory cytokines are required for GP-vaccine-mediated protection. Importantly, retention of protection in the setting of partial CD4 T depletion suggests a pathway for vaccinating at-risk immunocompromised individuals.

Citing Articles

Will the Real Immunogens Please Stand Up: Exploiting the Immunogenic Potential of Cryptococcal Cell Antigens in Fungal Vaccine Development.

Avina S, Pawar S, Rivera A, Xue C J Fungi (Basel). 2024; 10(12).

PMID: 39728336 PMC: 11676676. DOI: 10.3390/jof10120840.


State of the Field: Cytotoxic Immune Cell Responses in and Infection.

Okafor E, Nielsen K J Fungi (Basel). 2024; 10(10).

PMID: 39452664 PMC: 11508571. DOI: 10.3390/jof10100712.


Immunological correlates of protection mediated by a whole organism, , vaccine deficient in chitosan.

Specht C, Wang R, Oliveira L, Hester M, Gomez C, Mou Z mBio. 2024; 15(8):e0174624.

PMID: 38980038 PMC: 11323574. DOI: 10.1128/mbio.01746-24.


Protection against experimental cryptococcosis elicited by Cationic Adjuvant Formulation 01-adjuvanted subunit vaccines.

Wang R, Oliveira L, Hester M, Carlson D, Christensen D, Specht C PLoS Pathog. 2024; 20(7):e1012220.

PMID: 38976694 PMC: 11257399. DOI: 10.1371/journal.ppat.1012220.


Inbred Mouse Models in Research.

Ding M, Nielsen K J Fungi (Basel). 2024; 10(6).

PMID: 38921412 PMC: 11204852. DOI: 10.3390/jof10060426.


References
1.
De Benedetti F, Prencipe G, Bracaglia C, Marasco E, Grom A . Targeting interferon-γ in hyperinflammation: opportunities and challenges. Nat Rev Rheumatol. 2021; 17(11):678-691. DOI: 10.1038/s41584-021-00694-z. View

2.
Specht C, Lee C, Huang H, Hester M, Liu J, Luckie B . Vaccination with Recombinant Proteins in Glucan Particles Protects Mice against Cryptococcosis in a Manner Dependent upon Mouse Strain and Cryptococcal Species. mBio. 2017; 8(6). PMC: 5705919. DOI: 10.1128/mBio.01872-17. View

3.
Nanjappa S, Heninger E, Wuthrich M, Gasper D, Klein B . Tc17 cells mediate vaccine immunity against lethal fungal pneumonia in immune deficient hosts lacking CD4+ T cells. PLoS Pathog. 2012; 8(7):e1002771. PMC: 3400565. DOI: 10.1371/journal.ppat.1002771. View

4.
Gaffen S, Jain R, Garg A, Cua D . The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol. 2014; 14(9):585-600. PMC: 4281037. DOI: 10.1038/nri3707. View

5.
Stott K, Loyse A, Jarvis J, Alufandika M, Harrison T, Mwandumba H . Cryptococcal meningoencephalitis: time for action. Lancet Infect Dis. 2021; 21(9):e259-e271. DOI: 10.1016/S1473-3099(20)30771-4. View